Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHA: 600436)
China
· Delayed Price · Currency is CNY 246.60
+2.01 (0.82%)
Nov 18, 2024, 3:00 PM CST
Zhangzhou Pientzehuang Pharmaceutical., Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 3,079 | 2,797 | 2,472 | 2,432 | 1,672 | 1,374 | Upgrade
|
| Depreciation & Amortization | 102.38 | 102.38 | 80.36 | 133.49 | 90.21 | 55.89 | Upgrade
|
| Other Amortization | 26.31 | 26.31 | 15.34 | 15.96 | 12.46 | 10.69 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1.5 | -1.5 | -11.48 | -28.91 | -40.95 | -5.18 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.54 | 0.54 | 1.8 | 2.34 | 0.66 | 6.69 | Upgrade
|
| Loss (Gain) From Sale of Investments | -134.51 | -134.51 | -75.19 | -23.35 | -61.94 | -20.28 | Upgrade
|
| Provision & Write-off of Bad Debts | 12.27 | 12.27 | -6.78 | 7.1 | 2.95 | - | Upgrade
|
| Other Operating Activities | -1,273 | 89.36 | 123.88 | 100.42 | 62.25 | 46.5 | Upgrade
|
| Change in Accounts Receivable | -181.92 | -181.92 | 4,258 | -2,089 | -222.1 | -2,073 | Upgrade
|
| Change in Inventory | -758.78 | -758.78 | -199.39 | -261.56 | -74.87 | -429.56 | Upgrade
|
| Change in Accounts Payable | 306.43 | 306.43 | 205.02 | 232.58 | 39.54 | 160.98 | Upgrade
|
| Operating Cash Flow | 1,126 | 2,207 | 6,873 | 462.27 | 1,467 | -879.37 | Upgrade
|
| Operating Cash Flow Growth | -63.46% | -67.89% | 1386.79% | -68.49% | - | - | Upgrade
|
| Capital Expenditures | -118.52 | -141.87 | -175.37 | -92.17 | -419.01 | -65.44 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.9 | 1.25 | 13.74 | 5.31 | 86.19 | 13.18 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -1.91 | 57.33 | Upgrade
|
| Investment in Securities | -2,759 | -2,658 | -6,170 | 143.32 | 15.04 | 42.9 | Upgrade
|
| Other Investing Activities | 3,672 | 24.12 | 27.03 | 21.82 | 37.66 | 17.87 | Upgrade
|
| Investing Cash Flow | 796.25 | -2,774 | -6,305 | 78.29 | -282.03 | 67.84 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 1,410 | 1,058 | 1,162 | Upgrade
|
| Long-Term Debt Issued | - | 1,198 | 1,593 | - | - | - | Upgrade
|
| Total Debt Issued | 1,237 | 1,198 | 1,593 | 1,410 | 1,058 | 1,162 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -1,356 | -1,062 | -1,065 | Upgrade
|
| Long-Term Debt Repaid | - | -1,180 | -1,429 | -31.79 | - | - | Upgrade
|
| Total Debt Repaid | -1,080 | -1,180 | -1,429 | -1,387 | -1,062 | -1,065 | Upgrade
|
| Net Debt Issued (Repaid) | 157 | 17.85 | 164.12 | 23.09 | -4.46 | 96.41 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 679.15 | Upgrade
|
| Common Dividends Paid | -1,433 | -784.64 | -760.63 | -569.21 | -522.34 | -392.61 | Upgrade
|
| Other Financing Activities | -9.97 | -2.51 | 20.69 | 5.9 | -9.72 | 21.94 | Upgrade
|
| Financing Cash Flow | -1,286 | -769.3 | -575.82 | -540.23 | -536.52 | 404.89 | Upgrade
|
| Foreign Exchange Rate Adjustments | 3.38 | 2.43 | 11.44 | -4.62 | -6.26 | 4.87 | Upgrade
|
| Net Cash Flow | 639.66 | -1,334 | 3.84 | -4.29 | 642.26 | -401.77 | Upgrade
|
| Free Cash Flow | 1,007 | 2,065 | 6,698 | 370.11 | 1,048 | -944.81 | Upgrade
|
| Free Cash Flow Growth | -65.47% | -69.17% | 1709.66% | -64.69% | - | - | Upgrade
|
| Free Cash Flow Margin | 9.24% | 20.53% | 77.04% | 4.61% | 16.10% | -16.51% | Upgrade
|
| Free Cash Flow Per Share | 1.67 | 3.42 | 11.11 | 0.61 | 1.74 | -1.57 | Upgrade
|
| Cash Income Tax Paid | 1,117 | 1,155 | 989.67 | 969.09 | 821.62 | 622.26 | Upgrade
|
| Levered Free Cash Flow | 1,774 | 1,411 | 1,370 | 1,610 | 779.44 | 671 | Upgrade
|
| Unlevered Free Cash Flow | 1,797 | 1,434 | 1,394 | 1,631 | 796.56 | 690.45 | Upgrade
|
| Change in Net Working Capital | 410.25 | 571.16 | 307.14 | 143.65 | 6.85 | 285.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.